Vista Partners Initiates Coverage on OncoSec Medical Inc.; Target Price $2.90
SAN FRANCISCO, May 26, 2011 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage of OncoSec Medical Inc. (OTCBB: ONCS) ("the Company") with a twelve month target price of $2.90. Ross Silver, Principal Analyst at Vista Partners stated, "OncoSec's ElectroOncology clinical development pipeline is comprised of cancer treatments intended to address therapeutic needs in multi-billion dollar markets. The company's ElectroChemotherapy has shown in clinical trials to date that it selectively destroys cancer cells while leaving healthy tissue intact, dramatically improving patient quality of life. This provides OncoSec with a considerable potential competitive advantage compared to existing treatment options." Mr. Silver concludes, "OncoSec's ElectroImmunotherapy could prove to be a powerful new approach to treat local and metastatic tumors."
To download a FREE copy of the OncoSec Medical Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.
About Vista Partners:
Vista Partners LLC was founded in 2005 and has offices in California and one in Oregon. Vista Partners LLC is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.
Contact:877.215.4813 or email@example.com
SOURCE Vista Partners